ESMO: No Benefit to Cetuximab with Adjuvant Chemotherapy in Resected Stage III Colon Cancer

Share this content:
(ChemotherapyAdvisor) – Adding cetuximab to adjuvant FOLFOX4 did not show a benefit in patients with resected stage III KRAS mutant (mKRAS) colorectal cancer, results of a randomized phase 3 trial reported during the European Society for Medical Oncology 2012 Congress in Vienna, Austria.

The rationale for the European Pan-European Trials in Alimentary Tract Cancer (PETACC) 8 Intergroup Trial was based on a previous finding that adding cetuximab to FOLFOX was beneficial in patients with metastatic KRAS wild-type (wt) colon cancer. However, these negative results echo those of the US N0147 study, which also failed to show a benefit when cetuximab was added to mFOLFOX6, reported Dr. Julien Taieb of the Georges Pompidou European Hospital, Paris, France.

Patients were randomized 28-56 days following resection to 12 biweekly cycles of oxaliplatin 85mg/m2 on day 1, with leucovorin 200mg/m2 and 5-FU400 mg/m2 bolus IV followed by 5-FU 600mg/m2 over 22 hours IV on days 1-2 (FOLFOX4), without (arm A) or with (arm B) weekly cetuximab 250 g/m2 (loading dose 400mg/m2).

At a median follow-up of 45.4 months, no difference was observed between the arms for disease-free survival (DFS; HR 1.06; 95% CI, 0.82–1.37; P=0.65). Three-year DFS was 71.0% (95% CI, 66.0–75.3) in arm A and 70.7% (95% CI 65.6–75.1) in arm B.

Grade 3 or higher adverse events were significantly increased in arm B (81%) vs arm A (68.4%; RR 1.18; 95% CI, 1.09–1.29), as were diarrhea, asthenia, mucositis, skin disorders (grade ≥3) and failure to complete 12 cycles.

Dr. Taieb noted that “cetuximab may have a different form of activity in micrometastatic disease compared with that observed in stage IV disease” as a possible explanation for why cetuximab did not provide any additional benefit in this setting.

The study was supported by Merck-Serono and Sanofi-Aventis.

Abstract (520O)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs